Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is facing some temporary headwinds due to recent changes in Medicare reimbursement, but the company's strong track record, clinical data, and market relationships make it well-positioned to outperform in the long-term. Additionally, the company's cost reduction initiatives and vertical integration in manufacturing give it a competitive advantage, and the company's international and advanced surgical segments provide stability despite the challenges in the wound care market. There is potential for significant upside in the stock as demand patterns normalize and the company sees improvements in volume and revenue.

Bears say

MiMedx Group is facing risks related to tissue donorship, competition in the "minimal manipulation" skin substitute world, and the termination or expiration of agreements with GPOs and IDNs, which could negatively impact its future business and revenue. Additionally, the company's financials may be impacted by a one-time restructuring charge and the need for efficient tissue sourcing to meet future demand. However, MiMedx has a strong portfolio of amniograft products for various healthcare applications and is supported by peer-reviewed data and evidence of economic benefit.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.